Talis Biomedical (NASDAQ:TLIS) vs. Bio-Rad Laboratories (NYSE:BIO) Head to Head Comparison

Bio-Rad Laboratories (NYSE:BIO) and Talis Biomedical (NASDAQ:TLIS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Bio-Rad Laboratories and Talis Biomedical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Rad Laboratories $2.55 billion 7.05 $3.81 billion $10.52 57.32
Talis Biomedical $10.94 million 24.28 -$91.13 million N/A N/A

Bio-Rad Laboratories has higher revenue and earnings than Talis Biomedical.


This table compares Bio-Rad Laboratories and Talis Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories 151.73% 4.55% 3.40%
Talis Biomedical N/A N/A N/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bio-Rad Laboratories and Talis Biomedical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories 0 0 3 0 3.00
Talis Biomedical 0 1 3 0 2.75

Bio-Rad Laboratories currently has a consensus target price of $700.00, indicating a potential upside of 16.09%. Talis Biomedical has a consensus target price of $15.75, indicating a potential upside of 52.03%. Given Talis Biomedical’s higher possible upside, analysts plainly believe Talis Biomedical is more favorable than Bio-Rad Laboratories.

Institutional and Insider Ownership

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 81.6% of Talis Biomedical shares are held by institutional investors. 27.7% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


Bio-Rad Laboratories beats Talis Biomedical on 7 of the 10 factors compared between the two stocks.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.